Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses practical considerations for treating patients with IDH-mutated acute myeloid leukemia. Dr Marvin-Peek highlights the importance of managing toxicities and adjusting therapy duration based on patient tolerability.
Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses current therapeutic options for younger patients with acute myeloid leukemia. Dr Fathi notes that the approved guidance for…
In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…
In an interview conducted at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy, Gail J. Roboz, MD, professor of medicine and director of the…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
In this update, Ashley Yocum, PhD, executive research strategy lead of the Beat AML Master Trial at the Leukemia & Lymphoma Society, provides insights into the Beat AML…
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses a recent study on the use of APR-246 for the treatment of myelodysplastic syndrome…
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Fatima Tuz Zahra, MD, a hematology/oncology fellow at Moffitt Cancer Center, University of South Florida, Tampa, presented real-world data from a retrospective study evaluating the effectiveness of oral…
